Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Toll-Like Receptor 9 Activation Rescues Impaired Antibody Response in Needle-free Intradermal DNA Vaccination.

Arunachalam PS, Mishra R, Badarinath K, Selvam D, Payeli SK, Stout RR, Ranga U.

Sci Rep. 2016 Sep 23;6:33564. doi: 10.1038/srep33564.

2.

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.

Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, Moshiro C, Aboud S, Lyamuya E, Maboko L, Missanga M, Kaluwa B, Mfinanga S, Podola L, Bauer A, Godoy-Ramirez K, Marovich M, Moss B, Hoelscher M, Gotch F, Stöhr W, Stout R, McCormack S, Wahren B, Mhalu F, Robb ML, Biberfeld G, Sandström E, Bakari M.

PLoS One. 2015 Apr 15;10(4):e0119629. doi: 10.1371/journal.pone.0119629.

3.

A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice.

Bråve A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K, Blomberg P, Stout R, Paulie S, Sandström E, Biberfeld G, Earl P, Moss B, Cox JH, Wahren B.

Mol Ther. 2007 Sep;15(9):1724-1733. doi: 10.1038/sj.mt.6300235.

Supplemental Content

Loading ...
Support Center